Literature DB >> 11741399

Formation of filamentous tau aggregations in transgenic mice expressing V337M human tau.

K Tanemura1, T Akagi, M Murayama, N Kikuchi, O Murayama, T Hashikawa, Y Yoshiike, J M Park, K Matsuda, S Nakao, X Sun, S Sato, H Yamaguchi, A Takashima.   

Abstract

Formation of neurofibrillary tangles (NFTs) is the most common feature in several neurodegenerative diseases, including Alzheimer's disease (AD). Here we report the formation of filamentous tau aggregations having a beta-sheet structure in transgenic mice expressing mutant human tau. These mice contain a tau gene with a mutation of the frontotemporal dementia parkinsonism (FTDP-17) type, in which valine is substituted with methionine residue 337. The aggregation of tau in these transgenic mice satisfies all histological criteria used to identify NFTs common to human neurodegenerative diseases. These mice, therefore, provide a preclinical model for the testing of therapeutic drugs for the treatment of neurodegenerative disorders that exhibit NFTs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11741399     DOI: 10.1006/nbdi.2001.0439

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  36 in total

1.  Aggregation of detergent-insoluble tau is involved in neuronal loss but not in synaptic loss.

Authors:  Tetsuya Kimura; Tetsuya Fukuda; Naruhiko Sahara; Shunji Yamashita; Miyuki Murayama; Tatsuya Mizoroki; Yuji Yoshiike; Boyoung Lee; Ioannis Sotiropoulos; Sumihiro Maeda; Akihiko Takashima
Journal:  J Biol Chem       Date:  2010-10-04       Impact factor: 5.157

2.  Amyloid precursor protein and tau transgenic models of Alzheimer's disease: insights from the past and directions for the future.

Authors:  Naruhiko Sahara; Jada Lewis
Journal:  Future Neurol       Date:  2010-05-01

Review 3.  Transgenic mouse models of Alzheimer disease: developing a better model as a tool for therapeutic interventions.

Authors:  Masashi Kitazawa; Rodrigo Medeiros; Frank M Laferla
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 4.  Knock-out and transgenic mouse models of tauopathies.

Authors:  Franziska Denk; Richard Wade-Martins
Journal:  Neurobiol Aging       Date:  2007-06-22       Impact factor: 4.673

Review 5.  Murine models of Alzheimer's disease and their use in developing immunotherapies.

Authors:  Thomas Wisniewski; Einar M Sigurdsson
Journal:  Biochim Biophys Acta       Date:  2010-05-13

Review 6.  Modulation and detection of tau aggregation with small-molecule ligands.

Authors:  Edward Chang; Nicolette S Honson; Bhaswati Bandyopadhyay; Kristen E Funk; Jordan R Jensen; Sohee Kim; Swati Naphade; Jeff Kuret
Journal:  Curr Alzheimer Res       Date:  2009-10       Impact factor: 3.498

Review 7.  Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models.

Authors:  Thomas Wisniewski; Allal Boutajangout
Journal:  Brain Struct Funct       Date:  2009-12-10       Impact factor: 3.270

Review 8.  Interactions between Microtubule-Associated Protein Tau (MAPT) and Small Molecules.

Authors:  Jennifer N Rauch; Steven H Olson; Jason E Gestwicki
Journal:  Cold Spring Harb Perspect Med       Date:  2017-07-05       Impact factor: 6.915

9.  Gene Therapy Models of Alzheimer's Disease and Other Dementias.

Authors:  Benjamin Combs; Andrew Kneynsberg; Nicholas M Kanaan
Journal:  Methods Mol Biol       Date:  2016

Review 10.  Improved behavioral response as a valid biomarker for drug screening program in transgenic rodent models of tauopathies.

Authors:  Miroslava Korenova; Zuzana Stozicka
Journal:  Cell Mol Neurobiol       Date:  2009-03-13       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.